2024 Q1 Form 10-K Financial Statement
#000095017024021651 Filed on February 28, 2024
Income Statement
Concept | 2024 Q1 | 2023 Q4 | 2023 |
---|---|---|---|
Revenue | $13.05M | $51.13M | |
YoY Change | -28.31% | -61.21% | |
Cost Of Revenue | |||
YoY Change | |||
Gross Profit | |||
YoY Change | |||
Gross Profit Margin | |||
Selling, General & Admin | $8.648M | $33.65M | |
YoY Change | 8.93% | 3.79% | |
% of Gross Profit | |||
Research & Development | $32.97M | $35.27M | $133.6M |
YoY Change | 3.58% | 17.98% | 12.2% |
% of Gross Profit | |||
Depreciation & Amortization | $501.0K | $506.0K | $1.951M |
YoY Change | 13.61% | 11.21% | -1.37% |
% of Gross Profit | |||
Operating Expenses | $41.59M | $43.91M | $167.4M |
YoY Change | 3.05% | 16.08% | 10.37% |
Operating Profit | $10.82M | -$116.2M | |
YoY Change | -131.19% | 487.11% | |
Interest Expense | $3.073M | $13.16M | |
YoY Change | 2.81% | 121.65% | |
% of Operating Profit | |||
Other Income/Expense, Net | $2.975M | -$46.00K | $13.05M |
YoY Change | -11.35% | -453.85% | 121.25% |
Pretax Income | $13.79M | -$27.84M | -$103.2M |
YoY Change | -144.03% | 67.41% | 642.29% |
Income Tax | $629.0K | $190.0K | -$9.383M |
% Of Pretax Income | 4.56% | ||
Net Earnings | $13.16M | -$28.03M | -$93.80M |
YoY Change | -137.67% | -11.46% | 222.91% |
Net Earnings / Revenue | -214.84% | -183.44% | |
Basic Earnings Per Share | $0.31 | -$2.23 | |
Diluted Earnings Per Share | $0.30 | -$0.67 | -$2.23 |
COMMON SHARES | |||
Basic Shares Outstanding | 42.18M | 42.13M | 42.09M |
Diluted Shares Outstanding | 44.02M | 42.09M |
Balance Sheet
Concept | 2024 Q1 | 2023 Q4 | 2023 |
---|---|---|---|
SHORT-TERM ASSETS | |||
Cash & Short-Term Investments | $223.6M | $223.6M | |
YoY Change | -34.98% | -34.98% | |
Cash & Equivalents | $103.2M | $111.3M | $111.3M |
Short-Term Investments | $112.4M | $112.4M | |
Other Short-Term Assets | $4.749M | $4.749M | |
YoY Change | -16.9% | -16.9% | |
Inventory | |||
Prepaid Expenses | $3.463M | $4.749M | |
Receivables | |||
Other Receivables | $3.377M | $4.499M | |
Total Short-Term Assets | $254.7M | $243.7M | $243.7M |
YoY Change | -21.77% | -31.16% | -31.16% |
LONG-TERM ASSETS | |||
Property, Plant & Equipment | $3.714M | $4.215M | $7.541M |
YoY Change | -31.17% | -0.31% | -21.44% |
Goodwill | |||
YoY Change | |||
Intangibles | |||
YoY Change | |||
Long-Term Investments | |||
YoY Change | |||
Other Assets | $307.0K | $396.0K | $396.0K |
YoY Change | -24.75% | -20.32% | -20.32% |
Total Long-Term Assets | $8.414M | $10.21M | $10.21M |
YoY Change | -21.95% | 1.16% | 1.16% |
TOTAL ASSETS | |||
Total Short-Term Assets | $254.7M | $243.7M | $243.7M |
Total Long-Term Assets | $8.414M | $10.21M | $10.21M |
Total Assets | $263.1M | $253.9M | $253.9M |
YoY Change | -21.77% | -30.26% | -30.26% |
SHORT-TERM LIABILITIES | |||
YoY Change | |||
Accounts Payable | $6.825M | $2.400M | $2.400M |
YoY Change | 88.54% | 420.61% | 420.61% |
Accrued Expenses | $26.26M | $26.26M | |
YoY Change | 11.54% | 11.54% | |
Deferred Revenue | $1.073M | $10.22M | |
YoY Change | -97.97% | -80.75% | |
Short-Term Debt | $0.00 | $0.00 | |
YoY Change | |||
Long-Term Debt Due | |||
YoY Change | |||
Total Short-Term Liabilities | $30.57M | $39.08M | $39.08M |
YoY Change | -62.23% | -50.29% | -50.29% |
LONG-TERM LIABILITIES | |||
Long-Term Debt | $0.00 | $0.00 | |
YoY Change | |||
Other Long-Term Liabilities | $2.740M | $2.740M | |
YoY Change | -53.86% | -53.86% | |
Total Long-Term Liabilities | $2.740M | $2.740M | |
YoY Change | -53.86% | -53.86% | |
TOTAL LIABILITIES | |||
Total Short-Term Liabilities | $30.57M | $39.08M | $39.08M |
Total Long-Term Liabilities | $2.740M | $2.740M | |
Total Liabilities | $31.13M | $41.82M | $41.82M |
YoY Change | -63.4% | -50.54% | -50.54% |
SHAREHOLDERS EQUITY | |||
Retained Earnings | -$319.9M | -$333.1M | |
YoY Change | 16.66% | 39.2% | |
Common Stock | $552.0M | $545.2M | |
YoY Change | 5.0% | 4.99% | |
Preferred Stock | |||
YoY Change | |||
Treasury Stock (at cost) | |||
YoY Change | |||
Treasury Stock Shares | |||
Shareholders Equity | $232.0M | $212.1M | $212.1M |
YoY Change | |||
Total Liabilities & Shareholders Equity | $263.1M | $253.9M | $253.9M |
YoY Change | -21.77% | -30.26% | -30.26% |
Cashflow Statement
Concept | 2024 Q1 | 2023 Q4 | 2023 |
---|---|---|---|
OPERATING ACTIVITIES | |||
Net Income | $13.16M | -$28.03M | -$93.80M |
YoY Change | -137.67% | -11.46% | 222.91% |
Depreciation, Depletion And Amortization | $501.0K | $506.0K | $1.951M |
YoY Change | 13.61% | 11.21% | -1.37% |
Cash From Operating Activities | $11.93M | -$28.16M | -$127.2M |
YoY Change | -137.54% | -5.0% | -39590.06% |
INVESTING ACTIVITIES | |||
Capital Expenditures | $0.00 | $398.0K | $1.938M |
YoY Change | -100.0% | -123.14% | 221.93% |
Acquisitions | |||
YoY Change | |||
Other Investing Activities | $32.28M | $79.98M | |
YoY Change | -0.19% | -145.66% | |
Cash From Investing Activities | -$20.32M | $31.88M | $78.04M |
YoY Change | 203.86% | -6.4% | -144.4% |
FINANCING ACTIVITIES | |||
Cash Dividend Paid | |||
YoY Change | |||
Common Stock Issuance & Retirement, Net | |||
YoY Change | |||
Debt Paid & Issued, Net | |||
YoY Change | |||
Cash From Financing Activities | 375.0K | 105.0K | 842.0K |
YoY Change | -9.2% | -36.36% | -4.32% |
NET CHANGE | |||
Cash From Operating Activities | 11.93M | -28.16M | -127.2M |
Cash From Investing Activities | -20.32M | 31.88M | 78.04M |
Cash From Financing Activities | 375.0K | 105.0K | 842.0K |
Net Change In Cash | -8.051M | 3.828M | -48.25M |
YoY Change | -78.85% | -16.53% | -72.41% |
FREE CASH FLOW | |||
Cash From Operating Activities | $11.93M | -$28.16M | -$127.2M |
Capital Expenditures | $0.00 | $398.0K | $1.938M |
Free Cash Flow | $11.93M | -$28.55M | -$129.1M |
YoY Change | -136.99% | 2.28% | 46005.71% |
Facts In Submission
Frame | Concept Type | Concept / XBRL Key | Value | Unit |
---|---|---|---|---|
CY2023 | dei |
Entity Central Index Key
EntityCentralIndexKey
|
0001808158 | |
CY2023 | dei |
Amendment Flag
AmendmentFlag
|
false | |
CY2023 | dei |
Document Fiscal Period Focus
DocumentFiscalPeriodFocus
|
FY | |
CY2023 | dei |
Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
|
A8 | |
CY2023 | dei |
Entity Tax Identification Number
EntityTaxIdentificationNumber
|
00-0000000 | |
CY2023Q4 | us-gaap |
Commitments And Contingencies
CommitmentsAndContingencies
|
||
CY2022Q4 | us-gaap |
Commitments And Contingencies
CommitmentsAndContingencies
|
||
CY2023 | us-gaap |
Preferred Stock Shares Authorized Unlimited
PreferredStockSharesAuthorizedUnlimited
|
Unlimited | |
CY2022 | us-gaap |
Preferred Stock Shares Authorized Unlimited
PreferredStockSharesAuthorizedUnlimited
|
Unlimited | |
CY2023 | us-gaap |
Common Stock Shares Authorized Unlimited
CommonStockSharesAuthorizedUnlimited
|
Unlimited | |
CY2022 | us-gaap |
Common Stock Shares Authorized Unlimited
CommonStockSharesAuthorizedUnlimited
|
Unlimited | |
CY2023 | rptx |
Income Tax Examination Year Subject To Examination
IncomeTaxExaminationYearSubjectToExamination
|
2017 2018 2019 2020 2021 2022 2023 | |
CY2023 | dei |
Document Type
DocumentType
|
10-K | |
CY2023 | dei |
Document Annual Report
DocumentAnnualReport
|
true | |
CY2023 | dei |
Document Period End Date
DocumentPeriodEndDate
|
2023-12-31 | |
CY2023 | dei |
Current Fiscal Year End Date
CurrentFiscalYearEndDate
|
--12-31 | |
CY2023 | dei |
Document Fiscal Year Focus
DocumentFiscalYearFocus
|
2023 | |
CY2023 | dei |
Document Transition Report
DocumentTransitionReport
|
false | |
CY2023 | dei |
Entity File Number
EntityFileNumber
|
001-39335 | |
CY2023 | dei |
Entity Registrant Name
EntityRegistrantName
|
Repare Therapeutics Inc. | |
CY2023 | dei |
Entity Address Address Line1
EntityAddressAddressLine1
|
7171 Frederick-Banting | |
CY2023 | dei |
Entity Address Address Line2
EntityAddressAddressLine2
|
Suite 270 | |
CY2023 | dei |
Entity Address City Or Town
EntityAddressCityOrTown
|
St-Laurent | |
CY2023 | dei |
Entity Address State Or Province
EntityAddressStateOrProvince
|
QC | |
CY2023 | dei |
Entity Address Country
EntityAddressCountry
|
CA | |
CY2023 | dei |
Entity Address Postal Zip Code
EntityAddressPostalZipCode
|
H4S 1Z9 | |
CY2023 | dei |
City Area Code
CityAreaCode
|
857 | |
CY2023 | dei |
Local Phone Number
LocalPhoneNumber
|
412-7018 | |
CY2023 | dei |
Security12b Title
Security12bTitle
|
Common Shares, no par value | |
CY2023 | dei |
Trading Symbol
TradingSymbol
|
RPTX | |
CY2023 | dei |
Security Exchange Name
SecurityExchangeName
|
NASDAQ | |
CY2023 | dei |
Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
|
No | |
CY2023 | dei |
Entity Voluntary Filers
EntityVoluntaryFilers
|
No | |
CY2023 | dei |
Entity Current Reporting Status
EntityCurrentReportingStatus
|
Yes | |
CY2023 | dei |
Entity Interactive Data Current
EntityInteractiveDataCurrent
|
Yes | |
CY2023 | dei |
Entity Filer Category
EntityFilerCategory
|
Accelerated Filer | |
CY2023 | dei |
Entity Small Business
EntitySmallBusiness
|
true | |
CY2023 | dei |
Entity Emerging Growth Company
EntityEmergingGrowthCompany
|
false | |
CY2023 | dei |
Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
|
true | |
CY2023 | dei |
Document Fin Stmt Error Correction Flag
DocumentFinStmtErrorCorrectionFlag
|
false | |
CY2023 | dei |
Entity Shell Company
EntityShellCompany
|
false | |
CY2023Q2 | dei |
Entity Public Float
EntityPublicFloat
|
383103514 | |
CY2024Q1 | dei |
Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
|
42182177 | |
CY2023 | dei |
Auditor Firm
AuditorFirmId
|
1263 | |
CY2023 | dei |
Auditor Name
AuditorName
|
Ernst & Young LLP | |
CY2023 | dei |
Auditor Location
AuditorLocation
|
Montréal, Canada | |
CY2023Q4 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
111268000 | |
CY2022Q4 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
159521000 | |
CY2023Q4 | us-gaap |
Marketable Securities Current
MarketableSecuritiesCurrent
|
112359000 | |
CY2022Q4 | us-gaap |
Marketable Securities Current
MarketableSecuritiesCurrent
|
184420000 | |
CY2023Q4 | us-gaap |
Income Taxes Receivable
IncomeTaxesReceivable
|
10813000 | |
CY2022Q4 | us-gaap |
Income Taxes Receivable
IncomeTaxesReceivable
|
0 | |
CY2023Q4 | us-gaap |
Other Receivables Net Current
OtherReceivablesNetCurrent
|
4499000 | |
CY2022Q4 | us-gaap |
Other Receivables Net Current
OtherReceivablesNetCurrent
|
4323000 | |
CY2023Q4 | us-gaap |
Prepaid Expense Current
PrepaidExpenseCurrent
|
4749000 | |
CY2022Q4 | us-gaap |
Prepaid Expense Current
PrepaidExpenseCurrent
|
5715000 | |
CY2023Q4 | us-gaap |
Assets Current
AssetsCurrent
|
243688000 | |
CY2022Q4 | us-gaap |
Assets Current
AssetsCurrent
|
353979000 | |
CY2023Q4 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
4215000 | |
CY2022Q4 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
4228000 | |
CY2023Q4 | us-gaap |
Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
|
3326000 | |
CY2022Q4 | us-gaap |
Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
|
5371000 | |
CY2023Q4 | us-gaap |
Income Taxes Receivable Noncurrent
IncomeTaxesReceivableNoncurrent
|
2276000 | |
CY2022Q4 | us-gaap |
Income Taxes Receivable Noncurrent
IncomeTaxesReceivableNoncurrent
|
0 | |
CY2023Q4 | us-gaap |
Other Assets Noncurrent
OtherAssetsNoncurrent
|
396000 | |
CY2022Q4 | us-gaap |
Other Assets Noncurrent
OtherAssetsNoncurrent
|
497000 | |
CY2023Q4 | us-gaap |
Assets
Assets
|
253901000 | |
CY2022Q4 | us-gaap |
Assets
Assets
|
364075000 | |
CY2023Q4 | us-gaap |
Accounts Payable Current
AccountsPayableCurrent
|
2400000 | |
CY2022Q4 | us-gaap |
Accounts Payable Current
AccountsPayableCurrent
|
461000 | |
CY2023Q4 | us-gaap |
Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
|
24057000 | |
CY2022Q4 | us-gaap |
Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
|
21645000 | |
CY2023Q4 | us-gaap |
Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
|
2400000 | |
CY2022Q4 | us-gaap |
Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
|
2171000 | |
CY2023Q4 | us-gaap |
Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
|
10222000 | |
CY2022Q4 | us-gaap |
Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
|
53102000 | |
CY2023Q4 | us-gaap |
Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
|
0 | |
CY2022Q4 | us-gaap |
Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
|
1240000 | |
CY2023Q4 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
39079000 | |
CY2022Q4 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
78619000 | |
CY2023Q4 | us-gaap |
Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
|
1010000 | |
CY2022Q4 | us-gaap |
Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
|
3257000 | |
CY2023Q4 | us-gaap |
Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
|
1730000 | |
CY2022Q4 | us-gaap |
Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
|
2682000 | |
CY2023Q4 | us-gaap |
Liabilities
Liabilities
|
41819000 | |
CY2022Q4 | us-gaap |
Liabilities
Liabilities
|
84558000 | |
CY2023Q4 | us-gaap |
Preferred Stock No Par Value
PreferredStockNoParValue
|
0 | |
CY2022Q4 | us-gaap |
Preferred Stock No Par Value
PreferredStockNoParValue
|
0 | |
CY2023Q4 | us-gaap |
Preferred Stock Shares Issued
PreferredStockSharesIssued
|
0 | |
CY2022Q4 | us-gaap |
Preferred Stock Shares Issued
PreferredStockSharesIssued
|
0 | |
CY2023Q4 | us-gaap |
Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
|
0 | |
CY2022Q4 | us-gaap |
Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
|
0 | |
CY2023Q4 | us-gaap |
Preferred Stock Value
PreferredStockValue
|
0 | |
CY2022Q4 | us-gaap |
Preferred Stock Value
PreferredStockValue
|
0 | |
CY2023Q4 | us-gaap |
Common Stock No Par Value
CommonStockNoParValue
|
0 | |
CY2022Q4 | us-gaap |
Common Stock No Par Value
CommonStockNoParValue
|
0 | |
CY2023Q4 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
42176041 | |
CY2023Q4 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
42176041 | |
CY2022Q4 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
42036193 | |
CY2022Q4 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
42036193 | |
CY2023Q4 | us-gaap |
Common Stock Value
CommonStockValue
|
483350000 | |
CY2022Q4 | us-gaap |
Common Stock Value
CommonStockValue
|
482032000 | |
CY2023Q4 | us-gaap |
Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
|
61813000 | |
CY2022Q4 | us-gaap |
Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
|
37226000 | |
CY2023Q4 | us-gaap |
Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
|
28000 | |
CY2022Q4 | us-gaap |
Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
|
-428000 | |
CY2023Q4 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-333109000 | |
CY2022Q4 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-239313000 | |
CY2023Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
212082000 | |
CY2022Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
279517000 | |
CY2023Q4 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
253901000 | |
CY2022Q4 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
364075000 | |
CY2023 | rptx |
Revenue From Collaboration Agreements
RevenueFromCollaborationAgreements
|
51133000 | |
CY2022 | rptx |
Revenue From Collaboration Agreements
RevenueFromCollaborationAgreements
|
131830000 | |
CY2023 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
133593000 | |
CY2022 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
119066000 | |
CY2023 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
33764000 | |
CY2022 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
32560000 | |
CY2023 | us-gaap |
Operating Expenses
OperatingExpenses
|
167357000 | |
CY2022 | us-gaap |
Operating Expenses
OperatingExpenses
|
151626000 | |
CY2023 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-116224000 | |
CY2022 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-19796000 | |
CY2023 | us-gaap |
Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
|
-170000 | |
CY2022 | us-gaap |
Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
|
308000 | |
CY2023 | us-gaap |
Investment Income Net
InvestmentIncomeNet
|
13334000 | |
CY2022 | us-gaap |
Investment Income Net
InvestmentIncomeNet
|
5631000 | |
CY2023 | us-gaap |
Other Nonoperating Expense
OtherNonoperatingExpense
|
119000 | |
CY2022 | us-gaap |
Other Nonoperating Expense
OtherNonoperatingExpense
|
43000 | |
CY2023 | us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
13045000 | |
CY2022 | us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
5896000 | |
CY2023 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
|
-103179000 | |
CY2022 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
|
-13900000 | |
CY2023 | us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
-9383000 | |
CY2022 | us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
15147000 | |
CY2023 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-93796000 | |
CY2022 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-29047000 | |
CY2023 | us-gaap |
Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
|
456000 | |
CY2022 | us-gaap |
Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
|
-428000 | |
CY2023 | us-gaap |
Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
|
456000 | |
CY2022 | us-gaap |
Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
|
-428000 | |
CY2023 | us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
-93340000 | |
CY2022 | us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
-29475000 | |
CY2023 | us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
-2.23 | |
CY2023 | us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
-2.23 | |
CY2022 | us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
-0.69 | |
CY2022 | us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
-0.69 | |
CY2023 | us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
42093293 | |
CY2023 | us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
42093293 | |
CY2022 | us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
41922042 | |
CY2022 | us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
41922042 | |
CY2021Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
288421000 | |
CY2022 | us-gaap |
Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
|
447000 | |
CY2022 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
19691000 | |
CY2022 | us-gaap |
Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
|
-428000 | |
CY2022 | us-gaap |
Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest
IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
|
-29047000 | |
CY2022Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
279517000 | |
CY2023 | us-gaap |
Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
|
153000 | |
CY2023 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
25063000 | |
CY2023 | us-gaap |
Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
|
456000 | |
CY2023 | us-gaap |
Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest
IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
|
-93796000 | |
CY2023Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
212082000 | |
CY2023 | us-gaap |
Profit Loss
ProfitLoss
|
-93796000 | |
CY2022 | us-gaap |
Profit Loss
ProfitLoss
|
-29047000 | |
CY2023 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
25063000 | |
CY2022 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
19691000 | |
CY2023 | us-gaap |
Depreciation
Depreciation
|
1951000 | |
CY2022 | us-gaap |
Depreciation
Depreciation
|
1978000 | |
CY2023 | us-gaap |
Provision For Loan And Lease Losses
ProvisionForLoanAndLeaseLosses
|
2194000 | |
CY2022 | us-gaap |
Provision For Loan And Lease Losses
ProvisionForLoanAndLeaseLosses
|
2206000 | |
CY2023 | rptx |
Foreign Currency Transaction Gain Loss
ForeignCurrencyTransactionGainLoss
|
-78000 | |
CY2022 | rptx |
Foreign Currency Transaction Gain Loss
ForeignCurrencyTransactionGainLoss
|
298000 | |
CY2023 | us-gaap |
Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
|
7465000 | |
CY2022 | us-gaap |
Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
|
2233000 | |
CY2023 | us-gaap |
Increase Decrease In Deferred Income Taxes
IncreaseDecreaseInDeferredIncomeTaxes
|
0 | |
CY2022 | us-gaap |
Increase Decrease In Deferred Income Taxes
IncreaseDecreaseInDeferredIncomeTaxes
|
-3620000 | |
CY2023 | us-gaap |
Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
|
-969000 | |
CY2022 | us-gaap |
Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
|
-593000 | |
CY2023 | us-gaap |
Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
|
216000 | |
CY2022 | us-gaap |
Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
|
1385000 | |
CY2023 | us-gaap |
Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
|
-101000 | |
CY2022 | us-gaap |
Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
|
-89000 | |
CY2023 | us-gaap |
Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
|
1934000 | |
CY2022 | us-gaap |
Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
|
-1348000 | |
CY2023 | rptx |
Increase Decrease In Accrued Expenses And Other Current Liabilities
IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities
|
2412000 | |
CY2022 | rptx |
Increase Decrease In Accrued Expenses And Other Current Liabilities
IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities
|
3020000 | |
CY2023 | rptx |
Increase Decrease In Operating Lease Liability Current
IncreaseDecreaseInOperatingLeaseLiabilityCurrent
|
151000 | |
CY2022 | rptx |
Increase Decrease In Operating Lease Liability Current
IncreaseDecreaseInOperatingLeaseLiabilityCurrent
|
615000 | |
CY2023 | us-gaap |
Increase Decrease In Income Taxes
IncreaseDecreaseInIncomeTaxes
|
-14329000 | |
CY2022 | us-gaap |
Increase Decrease In Income Taxes
IncreaseDecreaseInIncomeTaxes
|
717000 | |
CY2023 | rptx |
Increase Decrease In Operating Lease Liability Net
IncreaseDecreaseInOperatingLeaseLiabilityNet
|
-2373000 | |
CY2022 | rptx |
Increase Decrease In Operating Lease Liability Net
IncreaseDecreaseInOperatingLeaseLiabilityNet
|
-2146000 | |
CY2023 | us-gaap |
Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
|
-43832000 | |
CY2022 | us-gaap |
Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
|
4250000 | |
CY2023 | us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-127158000 | |
CY2022 | us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
322000 | |
CY2023 | us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
1938000 | |
CY2022 | us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
602000 | |
CY2023 | us-gaap |
Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
|
259000000 | |
CY2022 | us-gaap |
Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
|
81400000 | |
CY2023 | us-gaap |
Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
|
179021000 | |
CY2022 | us-gaap |
Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
|
256576000 | |
CY2023 | us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
78041000 | |
CY2022 | us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
-175778000 | |
CY2023 | us-gaap |
Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
|
153000 | |
CY2022 | us-gaap |
Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
|
447000 | |
CY2023 | rptx |
Proceeds From Issuance Of Common Stock Under Two Thousand Twenty Employee Share Purchase Plan
ProceedsFromIssuanceOfCommonStockUnderTwoThousandTwentyEmployeeSharePurchasePlan
|
689000 | |
CY2022 | rptx |
Proceeds From Issuance Of Common Stock Under Two Thousand Twenty Employee Share Purchase Plan
ProceedsFromIssuanceOfCommonStockUnderTwoThousandTwentyEmployeeSharePurchasePlan
|
433000 | |
CY2023 | us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
842000 | |
CY2022 | us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
880000 | |
CY2023 | us-gaap |
Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
22000 | |
CY2022 | us-gaap |
Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
-330000 | |
CY2023 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
|
-48253000 | |
CY2022 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
|
-174906000 | |
CY2022Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
|
159521000 | |
CY2021Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
|
334427000 | |
CY2023Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
|
111268000 | |
CY2022Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
|
159521000 | |
CY2023 | us-gaap |
Interest Paid Net
InterestPaidNet
|
3089000 | |
CY2022 | us-gaap |
Interest Paid Net
InterestPaidNet
|
1966000 | |
CY2023 | us-gaap |
Income Taxes Paid
IncomeTaxesPaid
|
4945000 | |
CY2022 | us-gaap |
Income Taxes Paid
IncomeTaxesPaid
|
10810000 | |
CY2023 | us-gaap |
Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
|
149000 | |
CY2022 | us-gaap |
Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
|
86000 | |
CY2023 | dei |
Entity Incorporation Date Of Incorporation
EntityIncorporationDateOfIncorporation
|
2016-09-06 | |
CY2023Q4 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-333100000 | |
CY2023 | us-gaap |
Use Of Estimates
UseOfEstimates
|
<p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Use of Estimates</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in consolidated financial statements and accompanying notes. Significant estimates and assumptions reflected in these consolidated financial statements include, but are not limited to, estimates related to revenue recognition, accrued research and development expenses, share-based compensation, and income taxes. The Company bases its estimates on historical experience and other market specific or other relevant assumptions that it believes to be reasonable under the circumstances. Actual results could differ from those estimates. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p> | |
CY2023 | us-gaap |
Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
|
<p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Concentrations of Credit Risk and Off-Balance Sheet Risk</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash and cash equivalents and marketable securities. Our investment portfolio comprises money market funds, U.S. treasury securities, government-sponsored enterprises securities, and commercial paper. Our investment policy limits investment instruments to investment-grade securities with the objective to preserve capital and to maintain liquidity until the funds can be used in business operations.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company maintains deposits in accredited financial institutions which exceed insured limits. The Company deposits its cash in financial institutions that it believes have high credit quality and has not experienced any losses on such accounts and does not believe it is exposed to any unusual credit risk beyond the normal credit risk associated with commercial banking relationships.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company’s exposure to foreign exchange risk is primarily related to fluctuations between the Canadian dollar and the U.S. dollar. There are balances in Canadian dollars which are subject to foreign currency fluctuations relating to the impact of translating to U.S. dollars for financial statement presentation.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 and 2022</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, the Company had no significant off-balance sheet risk, such as foreign exchange contracts, option contracts or other foreign hedging arrangements.</span></span> | |
CY2023 | us-gaap |
Concentration Risk Credit Risk Financial Instruments Off Balance Sheet Risk
ConcentrationRiskCreditRiskFinancialInstrumentsOffBalanceSheetRisk
|
As of December 31, 2023 and 2022, the Company had no significant off-balance sheet risk, such as foreign exchange contracts, option contracts or other foreign hedging arrangements. | |
CY2022 | us-gaap |
Concentration Risk Credit Risk Financial Instruments Off Balance Sheet Risk
ConcentrationRiskCreditRiskFinancialInstrumentsOffBalanceSheetRisk
|
As of December 31, 2023 and 2022, the Company had no significant off-balance sheet risk, such as foreign exchange contracts, option contracts or other foreign hedging arrangements. | |
CY2023 | us-gaap |
Impairment Of Long Lived Assets To Be Disposed Of
ImpairmentOfLongLivedAssetsToBeDisposedOf
|
0 | |
CY2023 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Payments
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments
|
0 | |
CY2023Q4 | rptx |
Fair Value Assets Transfers Between All Levels
FairValueAssetsTransfersBetweenAllLevels
|
0 | |
CY2023Q4 | us-gaap |
Accrued Investment Income Receivable
AccruedInvestmentIncomeReceivable
|
400000 | |
CY2022Q4 | us-gaap |
Accrued Investment Income Receivable
AccruedInvestmentIncomeReceivable
|
400000 | |
CY2023Q4 | us-gaap |
Debt Securities Available For Sale Unrealized Loss Position
DebtSecuritiesAvailableForSaleUnrealizedLossPosition
|
58600000 | |
CY2022Q4 | us-gaap |
Debt Securities Available For Sale Unrealized Loss Position
DebtSecuritiesAvailableForSaleUnrealizedLossPosition
|
157900000 | |
CY2023 | us-gaap |
Debt Securities Available For Sale Allowance For Credit Loss Not Previously Recorded
DebtSecuritiesAvailableForSaleAllowanceForCreditLossNotPreviouslyRecorded
|
0 | |
CY2023 | us-gaap |
Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
|
500000 | |
CY2022 | us-gaap |
Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
|
-400000 | |
CY2022Q4 | rptx |
Fair Value Assets Transfers Between All Levels
FairValueAssetsTransfersBetweenAllLevels
|
0 | |
CY2023Q4 | rptx |
Research And Development Tax Credits Receivable
ResearchAndDevelopmentTaxCreditsReceivable
|
1319000 | |
CY2022Q4 | rptx |
Research And Development Tax Credits Receivable
ResearchAndDevelopmentTaxCreditsReceivable
|
1280000 | |
CY2023Q4 | us-gaap |
Receivables Long Term Contracts Or Programs
ReceivablesLongTermContractsOrPrograms
|
2050000 | |
CY2022Q4 | us-gaap |
Receivables Long Term Contracts Or Programs
ReceivablesLongTermContractsOrPrograms
|
1525000 | |
CY2023Q4 | rptx |
Sales Tax And Other Receivables Current
SalesTaxAndOtherReceivablesCurrent
|
1130000 | |
CY2022Q4 | rptx |
Sales Tax And Other Receivables Current
SalesTaxAndOtherReceivablesCurrent
|
1518000 | |
CY2023Q4 | us-gaap |
Other Receivables Net Current
OtherReceivablesNetCurrent
|
4499000 | |
CY2022Q4 | us-gaap |
Other Receivables Net Current
OtherReceivablesNetCurrent
|
4323000 | |
CY2023Q4 | us-gaap |
Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
|
11519000 | |
CY2022Q4 | us-gaap |
Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
|
9581000 | |
CY2023Q4 | us-gaap |
Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
|
7304000 | |
CY2022Q4 | us-gaap |
Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
|
5353000 | |
CY2023Q4 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
4215000 | |
CY2022Q4 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
4228000 | |
CY2023 | us-gaap |
Lessee Operating Lease Existence Of Option To Terminate
LesseeOperatingLeaseExistenceOfOptionToTerminate
|
false | |
CY2023 | us-gaap |
Depreciation
Depreciation
|
1951000 | |
CY2022 | us-gaap |
Depreciation
Depreciation
|
1978000 | |
CY2023Q4 | us-gaap |
Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
|
6981000 | |
CY2022Q4 | us-gaap |
Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
|
5616000 | |
CY2023Q4 | rptx |
Accrued Research And Development Expense Current
AccruedResearchAndDevelopmentExpenseCurrent
|
16251000 | |
CY2022Q4 | rptx |
Accrued Research And Development Expense Current
AccruedResearchAndDevelopmentExpenseCurrent
|
15078000 | |
CY2023Q4 | us-gaap |
Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
|
631000 | |
CY2022Q4 | us-gaap |
Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
|
680000 | |
CY2023Q4 | us-gaap |
Other Liabilities Current
OtherLiabilitiesCurrent
|
194000 | |
CY2022Q4 | us-gaap |
Other Liabilities Current
OtherLiabilitiesCurrent
|
271000 | |
CY2023Q4 | rptx |
Accrued Expenses And Other Liabilities Current
AccruedExpensesAndOtherLiabilitiesCurrent
|
24057000 | |
CY2022Q4 | rptx |
Accrued Expenses And Other Liabilities Current
AccruedExpensesAndOtherLiabilitiesCurrent
|
21645000 | |
CY2023 | rptx |
Number Of Operating Leases
NumberOfOperatingLeases
|
4 | |
CY2023 | us-gaap |
Operating Lease Cost
OperatingLeaseCost
|
2372000 | |
CY2022 | us-gaap |
Operating Lease Cost
OperatingLeaseCost
|
2456000 | |
CY2023 | us-gaap |
Short Term Lease Cost
ShortTermLeaseCost
|
122000 | |
CY2022 | us-gaap |
Short Term Lease Cost
ShortTermLeaseCost
|
33000 | |
CY2023 | us-gaap |
Variable Lease Cost
VariableLeaseCost
|
249000 | |
CY2022 | us-gaap |
Variable Lease Cost
VariableLeaseCost
|
278000 | |
CY2023 | us-gaap |
Lease Cost
LeaseCost
|
2743000 | |
CY2022 | us-gaap |
Lease Cost
LeaseCost
|
2767000 | |
CY2023 | us-gaap |
Operating Lease Payments
OperatingLeasePayments
|
2405000 | |
CY2022 | us-gaap |
Operating Lease Payments
OperatingLeasePayments
|
1948000 | |
CY2023 | us-gaap |
Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
|
149000 | |
CY2022 | us-gaap |
Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
|
86000 | |
CY2023Q4 | us-gaap |
Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
|
P1Y5M15D | |
CY2022Q4 | us-gaap |
Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
|
P2Y5M4D | |
CY2023Q4 | us-gaap |
Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
|
0.042 | |
CY2022Q4 | us-gaap |
Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
|
0.04 | |
CY2023 | rptx |
Implicit Interest Rate
ImplicitInterestRate
|
0 | |
CY2022 | rptx |
Implicit Interest Rate
ImplicitInterestRate
|
0 | |
CY2023Q4 | us-gaap |
Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
|
2490000 | |
CY2023Q4 | us-gaap |
Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
|
1022000 | |
CY2023Q4 | us-gaap |
Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
|
3512000 | |
CY2023Q4 | us-gaap |
Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
|
102000 | |
CY2023Q4 | us-gaap |
Operating Lease Liability
OperatingLeaseLiability
|
3410000 | |
CY2023Q4 | us-gaap |
Income Taxes Receivable
IncomeTaxesReceivable
|
10800000 | |
CY2023Q4 | us-gaap |
Income Taxes Receivable Noncurrent
IncomeTaxesReceivableNoncurrent
|
2300000 | |
CY2023 | rptx |
Income Tax Losses
IncomeTaxLosses
|
263800000 | |
CY2022Q4 | us-gaap |
Preferred Stock Shares Issued
PreferredStockSharesIssued
|
0 | |
CY2023Q4 | us-gaap |
Preferred Stock Shares Issued
PreferredStockSharesIssued
|
0 | |
CY2022Q4 | us-gaap |
Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
|
0 | |
CY2023Q4 | us-gaap |
Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
|
0 | |
CY2023 | us-gaap |
Common Stock Voting Rights
CommonStockVotingRights
|
Each common share entitles the holder to one vote on all matters submitted to the shareholders for a vote. | |
CY2023 | us-gaap |
Dividends Common Stock Cash
DividendsCommonStockCash
|
0 | |
CY2022Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
|
8032902 | |
CY2022Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
|
14.38 | |
CY2022 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
|
P7Y10M24D | |
CY2022Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
|
37250000 | |
CY2023 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
|
2371540 | |
CY2023 | us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
|
11.55 | |
CY2023 | us-gaap |
Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
|
64240 | |
CY2023 | us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
|
2.37 | |
CY2023 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
|
242431 | |
CY2023 | us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
|
15.2 | |
CY2023Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
|
10097771 | |
CY2023Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
|
13.77 | |
CY2023 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
|
P7Y4M28D | |
CY2023Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
|
13502000 | |
CY2023Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
|
5960917 | |
CY2023Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
|
13 | |
CY2023 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
|
P6Y7M13D | |
CY2023Q4 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
|
13000000 | |
CY2023Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
|
4136854 | |
CY2023Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
|
14.88 | |
CY2023 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
|
P8Y6M25D | |
CY2023Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
|
502000 | |
CY2023 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
|
500000 | |
CY2022 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
|
1700000 | |
CY2023 | rptx |
Fair Value Of Vested Options
FairValueOfVestedOptions
|
24400000 | |
CY2022 | rptx |
Fair Value Of Vested Options
FairValueOfVestedOptions
|
20100000 | |
CY2023 | us-gaap |
Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
|
64240 | |
CY2023 | us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
|
2.37 | |
CY2023 | us-gaap |
Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
|
200000 | |
CY2023 | rptx |
Additional Paid In Capital Share Based Payment Arrangement Exercised Options Credited To Common Shares
AdditionalPaidInCapitalShareBasedPaymentArrangementExercisedOptionsCreditedToCommonShares
|
100000 | |
CY2023 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
25063000 | |
CY2022 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
19691000 | |
CY2023 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
25063000 | |
CY2022 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
19691000 | |
CY2023 | rptx |
Defined Contribution Plan Employer Non Matching Contribution Percent
DefinedContributionPlanEmployerNonMatchingContributionPercent
|
0.03 | |
CY2023 | us-gaap |
Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
|
900000 | |
CY2022 | us-gaap |
Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
|
800000 | |
CY2023 | rptx |
Revenue From Collaboration Agreements
RevenueFromCollaborationAgreements
|
51133000 | |
CY2022 | rptx |
Revenue From Collaboration Agreements
RevenueFromCollaborationAgreements
|
131830000 | |
CY2023 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
|
-108362000 | |
CY2022 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
|
-17550000 | |
CY2023 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
|
5183000 | |
CY2022 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
|
3650000 | |
CY2023 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
|
-103179000 | |
CY2022 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
|
-13900000 | |
CY2023 | us-gaap |
Current Foreign Tax Expense Benefit
CurrentForeignTaxExpenseBenefit
|
-9383000 | |
CY2022 | us-gaap |
Current Foreign Tax Expense Benefit
CurrentForeignTaxExpenseBenefit
|
11527000 | |
CY2023 | us-gaap |
Deferred Foreign Income Tax Expense Benefit
DeferredForeignIncomeTaxExpenseBenefit
|
0 | |
CY2022 | us-gaap |
Deferred Foreign Income Tax Expense Benefit
DeferredForeignIncomeTaxExpenseBenefit
|
3620000 | |
CY2023 | us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
-9383000 | |
CY2022 | us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
15147000 | |
CY2023 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
|
-103179000 | |
CY2022 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
|
-13900000 | |
CY2023 | us-gaap |
Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
|
0.265 | |
CY2022 | us-gaap |
Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
|
0.265 | |
CY2023 | us-gaap |
Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
|
-27342000 | |
CY2022 | us-gaap |
Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
|
-3684000 | |
CY2023 | us-gaap |
Income Tax Reconciliation Tax Credits
IncomeTaxReconciliationTaxCredits
|
6648000 | |
CY2022 | us-gaap |
Income Tax Reconciliation Tax Credits
IncomeTaxReconciliationTaxCredits
|
4899000 | |
CY2023 | rptx |
Income Tax Rate Reconciliation Nondeductible Expense Accounting Charges
IncomeTaxRateReconciliationNondeductibleExpenseAccountingCharges
|
5132000 | |
CY2022 | rptx |
Income Tax Rate Reconciliation Nondeductible Expense Accounting Charges
IncomeTaxRateReconciliationNondeductibleExpenseAccountingCharges
|
679000 | |
CY2023 | rptx |
Income Tax Reconciliation Capital Gain Income Equity Compensation
IncomeTaxReconciliationCapitalGainIncomeEquityCompensation
|
0 | |
CY2022 | rptx |
Income Tax Reconciliation Capital Gain Income Equity Compensation
IncomeTaxReconciliationCapitalGainIncomeEquityCompensation
|
-13956000 | |
CY2023 | us-gaap |
Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost
IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
|
4292000 | |
CY2022 | us-gaap |
Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost
IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
|
3492000 | |
CY2023 | rptx |
Income Tax Reconciliation State Taxes
IncomeTaxReconciliationStateTaxes
|
643000 | |
CY2022 | rptx |
Income Tax Reconciliation State Taxes
IncomeTaxReconciliationStateTaxes
|
-777000 | |
CY2023 | us-gaap |
Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
|
26000 | |
CY2022 | us-gaap |
Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
|
-142000 | |
CY2023 | us-gaap |
Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
|
14514000 | |
CY2022 | us-gaap |
Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
|
34434000 | |
CY2023 | us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
-9383000 | |
CY2022 | us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
15147000 | |
CY2023Q4 | us-gaap |
Income Tax Receivable
IncomeTaxReceivable
|
13100000 | |
CY2023 | rptx |
Income Tax Losses Expire One
IncomeTaxLossesExpireOne
|
115959000 | |
CY2023 | rptx |
Income Tax Losses Expire Two
IncomeTaxLossesExpireTwo
|
34571000 | |
CY2023 | rptx |
Income Tax Losses Expire Three
IncomeTaxLossesExpireThree
|
93833000 | |
CY2023 | rptx |
Income Tax Losses Expire Four
IncomeTaxLossesExpireFour
|
0 | |
CY2023 | rptx |
Income Tax Losses Expire Five
IncomeTaxLossesExpireFive
|
11394000 | |
CY2023 | rptx |
Income Tax Losses Expire Six
IncomeTaxLossesExpireSix
|
7111000 | |
CY2023 | rptx |
Income Tax Losses Expire Seven
IncomeTaxLossesExpireSeven
|
883000 | |
CY2023 | rptx |
Income Tax Losses
IncomeTaxLosses
|
263751000 | |
CY2023 | rptx |
Scientific Research And Experimental Development Expenditures
ScientificResearchAndExperimentalDevelopmentExpenditures
|
70700000 | |
CY2023Q4 | rptx |
Investment Tax Credits
InvestmentTaxCredits
|
11700000 | |
CY2023Q4 | rptx |
Investment Tax Credits Expire One
InvestmentTaxCreditsExpireOne
|
2649000 | |
CY2023Q4 | rptx |
Investment Tax Credits Expire Two
InvestmentTaxCreditsExpireTwo
|
2433000 | |
CY2023Q4 | rptx |
Investment Tax Credits Expire Three
InvestmentTaxCreditsExpireThree
|
2253000 | |
CY2023Q4 | rptx |
Investment Tax Credits Expire Four
InvestmentTaxCreditsExpireFour
|
1702000 | |
CY2023Q4 | rptx |
Investment Tax Credits Expire Five
InvestmentTaxCreditsExpireFive
|
1362000 | |
CY2023Q4 | rptx |
Investment Tax Credits Expire Six
InvestmentTaxCreditsExpireSix
|
776000 | |
CY2023Q4 | rptx |
Investment Tax Credits Expire Seven
InvestmentTaxCreditsExpireSeven
|
455000 | |
CY2023Q4 | rptx |
Investment Tax Credits Expire Eight
InvestmentTaxCreditsExpireEight
|
24000 | |
CY2023Q4 | rptx |
Investment Tax Credits
InvestmentTaxCredits
|
11654000 | |
CY2023Q4 | us-gaap |
Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
|
69894000 | |
CY2022Q4 | us-gaap |
Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
|
42003000 | |
CY2023Q4 | us-gaap |
Deferred Tax Assets In Process Research And Development
DeferredTaxAssetsInProcessResearchAndDevelopment
|
18724000 | |
CY2022Q4 | us-gaap |
Deferred Tax Assets In Process Research And Development
DeferredTaxAssetsInProcessResearchAndDevelopment
|
14468000 | |
CY2023Q4 | us-gaap |
Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
|
1200000 | |
CY2022Q4 | us-gaap |
Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
|
2369000 | |
CY2023Q4 | rptx |
Deferred Tax Assets Net Federal Investment Tax Credits
DeferredTaxAssetsNetFederalInvestmentTaxCredits
|
8567000 | |
CY2022Q4 | rptx |
Deferred Tax Assets Net Federal Investment Tax Credits
DeferredTaxAssetsNetFederalInvestmentTaxCredits
|
6589000 | |
CY2023Q4 | us-gaap |
Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
|
4565000 | |
CY2022Q4 | us-gaap |
Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
|
0 | |
CY2023Q4 | us-gaap |
Deferred Tax Assets Property Plant And Equipment
DeferredTaxAssetsPropertyPlantAndEquipment
|
39000 | |
CY2022Q4 | us-gaap |
Deferred Tax Liabilities Property Plant And Equipment
DeferredTaxLiabilitiesPropertyPlantAndEquipment
|
376000 | |
CY2023Q4 | rptx |
Deferred Tax Liabilities Operating Lease Right Of Use Assets
DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets
|
-883000 | |
CY2022Q4 | rptx |
Deferred Tax Liabilities Operating Lease Right Of Use Assets
DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets
|
-1429000 | |
CY2023Q4 | rptx |
Deferred Tax Assets Operating Lease Liability
DeferredTaxAssetsOperatingLeaseLiability
|
906000 | |
CY2022Q4 | rptx |
Deferred Tax Assets Operating Lease Liability
DeferredTaxAssetsOperatingLeaseLiability
|
1445000 | |
CY2023Q4 | rptx |
Deferred Tax Assets Accrued Expense And Other Liabilities
DeferredTaxAssetsAccruedExpenseAndOtherLiabilities
|
1134000 | |
CY2022Q4 | rptx |
Deferred Tax Assets Accrued Expense And Other Liabilities
DeferredTaxAssetsAccruedExpenseAndOtherLiabilities
|
785000 | |
CY2023Q4 | us-gaap |
Deferred Tax Assets Deferred Income
DeferredTaxAssetsDeferredIncome
|
3167000 | |
CY2022Q4 | us-gaap |
Deferred Tax Assets Deferred Income
DeferredTaxAssetsDeferredIncome
|
14783000 | |
CY2023Q4 | rptx |
Deferred Tax Assets Share Based Compensation Cost
DeferredTaxAssetsShareBasedCompensationCost
|
4240000 | |
CY2022Q4 | rptx |
Deferred Tax Assets Share Based Compensation Cost
DeferredTaxAssetsShareBasedCompensationCost
|
2492000 | |
CY2023Q4 | rptx |
Deferred Tax Assets Deferred Expense Capitalized Research And Development Costs
DeferredTaxAssetsDeferredExpenseCapitalizedResearchAndDevelopmentCosts
|
0 | |
CY2022Q4 | rptx |
Deferred Tax Assets Deferred Expense Capitalized Research And Development Costs
DeferredTaxAssetsDeferredExpenseCapitalizedResearchAndDevelopmentCosts
|
13911000 | |
CY2023Q4 | us-gaap |
Deferred Tax Assets Gross
DeferredTaxAssetsGross
|
111553000 | |
CY2022Q4 | us-gaap |
Deferred Tax Assets Gross
DeferredTaxAssetsGross
|
97040000 | |
CY2023Q4 | us-gaap |
Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
|
111553000 | |
CY2022Q4 | us-gaap |
Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
|
97040000 | |
CY2023Q4 | us-gaap |
Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
|
0 | |
CY2022Q4 | us-gaap |
Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
|
0 | |
CY2023Q4 | us-gaap |
Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
|
111600000 | |
CY2022Q4 | us-gaap |
Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
|
97000000 | |
CY2023Q4 | us-gaap |
Unrecognized Tax Benefits
UnrecognizedTaxBenefits
|
0 | |
CY2022Q4 | us-gaap |
Unrecognized Tax Benefits
UnrecognizedTaxBenefits
|
0 | |
CY2023Q4 | us-gaap |
Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
|
0 | |
CY2022Q4 | us-gaap |
Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
|
0 | |
CY2023 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-93796000 | |
CY2022 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-29047000 | |
CY2023 | us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
42093293 | |
CY2023 | us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
42093293 | |
CY2022 | us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
41922042 | |
CY2022 | us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
41922042 | |
CY2023 | us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
-2.23 | |
CY2023 | us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
-2.23 | |
CY2022 | us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
-0.69 | |
CY2022 | us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
-0.69 | |
CY2023 | rptx |
Increase Decrease In Research And Development Expenses
IncreaseDecreaseInResearchAndDevelopmentExpenses
|
1500000 | |
CY2022 | rptx |
Increase Decrease In Research And Development Expenses
IncreaseDecreaseInResearchAndDevelopmentExpenses
|
1400000 | |
CY2023Q4 | us-gaap |
Contractual Obligation Due In Next Twelve Months
ContractualObligationDueInNextTwelveMonths
|
3107000 | |
CY2023Q4 | us-gaap |
Contractual Obligation Due In Second Year
ContractualObligationDueInSecondYear
|
33000 | |
CY2023Q4 | us-gaap |
Contractual Obligation Due In Third Year
ContractualObligationDueInThirdYear
|
57000 | |
CY2023Q4 | us-gaap |
Contractual Obligation Due In Fourth Year
ContractualObligationDueInFourthYear
|
33000 | |
CY2023Q4 | us-gaap |
Contractual Obligation Due In Fifth Year
ContractualObligationDueInFifthYear
|
41000 | |
CY2023Q4 | us-gaap |
Contractual Obligation Due After Fifth Year
ContractualObligationDueAfterFifthYear
|
173000 | |
CY2023Q4 | us-gaap |
Contractual Obligation
ContractualObligation
|
3444000 | |
CY2023Q4 | us-gaap |
Foreign Currency Derivative Instruments Not Designated As Hedging Instruments At Fair Value Net
ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAtFairValueNet
|
-3708000 | |
CY2022Q4 | us-gaap |
Foreign Currency Derivative Instruments Not Designated As Hedging Instruments At Fair Value Net
ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAtFairValueNet
|
-6056000 | |
CY2023 | rptx |
Percentage Of Depreciation Usd Against Canadian Dollar
PercentageOfDepreciationUSDAgainstCanadianDollar
|
0.10 | |
CY2023 | us-gaap |
Gain Loss On Foreign Currency Derivative Instruments Not Designated As Hedging Instruments
GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments
|
300000 | |
CY2023Q4 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
4215000 | |
CY2022Q4 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
4228000 | |
CY2023Q4 | us-gaap |
Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
|
3326000 | |
CY2022Q4 | us-gaap |
Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
|
5371000 |